Riskpilot← Back to searchSign inGet full accessPharmart AB
ABBankruptOrg 5569481822Retail sale of pharmaceutical products · NACE 4773Est. 20130 employees
Revenue 2023
SEK 18,6M
-52% vs 2022
EBITDA margin
-29.1%
-249% vs 2022
Equity ratio
7.0%
Financial strength
Net profit 2023
SEK -6,9M
-4373% vs 2022
| Revenue | SEK 18,6M | -52% |
| EBITDA | SEK -5,4M | -249% |
| Net profit | SEK -6,9M | -4373% |
| Total assets | SEK 10,6M | -47% |
| Equity | SEK 738K | -90% |
| Employees | 0 | — |
Legal name
Pharmart AB
Org number
5569481822
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
7 november 2013
Share capital
SEK 500 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas ensam av Ehrman, Per Göran Mikael
Company purpose
Bolaget ska driva apoteksverksamhet för öppenvård, försäljning av läkemedel och hälsokost samt verksamhet inom detaljhandel inom nämnda område med inriktning på postorder- och internethandel. Bolaget ska bedriva handel och försäljning av apoteksnära handelsvaror och egenvårdsprodukter.
Address
Phone
+46704836536
Email
mikael@iapotek.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 14 723 | 22 402 | 24 229 | 24 258 | 38 926 | 18 614 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | 1 660 | 1 014 | 1 894 | 1 917 | 3 031 | 2 464 | 2 114 | 3 623 | −5 416 |
| Depreciation & amort. | −56 | −62 | −68 | −64 | −49 | −9 | −2 | −1 466 | −1 466 |
| EBIT | 1 604 | 952 | 1 826 | 1 853 | 2 982 | 2 455 | 2 112 | 2 157 | −6 882 |
| Net financials | −4 | — | −103 | −39 | −2 | — | — | — | −5 |
| Profit before tax | 1 599 | 952 | 1 723 | 1 815 | 2 979 | 1 266 | −186 | −154 | −6 888 |
| Tax | −310 | −211 | −394 | −401 | −639 | −274 | −0 | −0 | −0 |
| Net profit | 1 289 | 741 | 1 329 | 1 414 | 2 340 | 992 | −186 | −154 | −6 888 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3 552 | 3 622 | 4 770 | 6 488 | 9 889 | 9 995 | 17 107 | 20 207 | 10 611 |
| Equity | 1 149 | 1 890 | 3 219 | 4 633 | 6 973 | 7 966 | 7 780 | 7 626 | 738 |
| Long-term debt | 500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 903 | 1 732 | 1 550 | 1 855 | 2 916 | 2 029 | 9 327 | 12 581 | 9 873 |
| Total debt | 2 403 | 1 732 | 1 550 | 1 855 | 2 916 | 2 029 | 9 327 | 12 581 | 9 873 |
EBITDA margin
-29.1%
This company
15.8%
Market median
-284% vs market
20152023
Equity ratio
7.0%
This company
38.2%
Market median
-82% vs market
20152023
Return on equity
-933.3%
This company
18.4%
Market median
-5172% vs market
20152023
Net profit margin
-37.0%
This company
8.1%
Market median
-557% vs market
20152023
Asset turnover
1.75×
This company
1.12×
Market median
+56% vs market
20152023
Debt / equity
13.38×
This company
0.62×
Market median
-2058% vs market
20152023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2014-11-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JR | Audit | 2022 | — | — |
SF Chief Auditor | Chief Auditor | 2022 | — | — |
PG Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
iApotek Int AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
iApotek Int AB
Pharmart AB Board members of Pharmart AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Richard Kaijser | Audit | 0 companies |
| Stefan Folke Adebahr | Chief Auditor | 0 companies |
| Per Göran Mikael Ehrman | Chief Executive Officer | 0 companies |
| Behrouz Rezakhani | Deputy Board Member | 0 companies |
| Göran Roger Hjalmarsson | Board of Directors | 0 companies |
| Jan Conny Palmkvist | Board of Directors | 0 companies |
| Jan Olof Martin Hamberg | Deputy Board Member | 0 companies |
| Freidoun André Albertioni | Chairman | 0 companies |
| Lars Joachim Rambe | Chairman | 0 companies |
| Bernt Magnus Nilsson | Chairman | 0 companies |
| Karl Jerker Gustav Vestin | Board of Directors | 0 companies |
| Marius Abel Lyszczarz | Board of Directors | 0 companies |